Superworth

Bristol-Myers Squibb forward PE BMY

Share price divided by analysts' consensus earnings for the next twelve months, since 1996.

Today, Oct 23, 2026
10.4×
10-year median
10.2×
Against its 10-year history
56th
percentile: 0 is its lowest day, 100 its highest
10-year range
6.6× to 405×
Peer median
18.8×

Bristol-Myers Squibb's forward PE is 10.4× as of Oct 23, 2026.

That is above its ten-year median of 10.2×, close to the middle of its last ten years.

Over that time it ranged from 6.6× in Jul 2024 to 405× in Mar 2024.

The median for 9 large drugmakers of a similar size is 18.8×.

Forward PE over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far10.4×9.2×11.4×
202510.2×7.6×11.5×
202410.4×6.6×405×
2023229×9.1×235×
20229.7×8.6×10.9×
20218.5×7.7×9.5×
20208.8×8.2×11.3×
201910.8×8.2×12.6×
201812.8×12.5×23.1×
201721.3×16.9×22.2×
201620.3×17.7×31.9×
201534.1×31.8×46.7×
201438.9×28.4×40.1×
201334.5×20.1×34.7×
201219.2×15.5×21.6×
201116.8×11.8×16.8×
201012.9×11.4×13.9×
200914.0×10.9×14.3×
200813.6×10.4×17.9×
200718.4×18.4×27.8×

Against its peers

Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.

CompanyForward PE
BMYBristol-Myers Squibb10.4×
PFEPfizer10.9×
GILDGilead Sciences17.2×
AMGNAmgen18.6×
MRKMerck17.5×
BIIBBiogen19.1×
ABBVAbbVie19.0×
JNJJohnson & Johnson23.4×
JAZZJazz Pharmaceuticalsn/m
LLYEli Lilly and33.9×
Peer median18.8×

Where Bristol-Myers Squibb ranks

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on Bristol-Myers Squibb

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.